To investigate the possibility of detecting sentinel lymph nodes (SNs) in patients with urinary bladder cancer (BCa) intra-operatively and whether the histopathological status of the identified SNs reflected that of the lymphatic field.
Introduction
Tumours invading the bladder muscle constitute~30% of urinary bladder carcinoma (BCa) [1] . Nearly 20-25% of such patients have pathological evidence of lymph node (LN) metastases after radical cystectomy (RC) [2] [3] [4] . As LN metastasis is associated with poor prognosis, RC combined with lymphadenectomy has become a routine surgical treatment for carcinoma invading the bladder muscle [5] . LN dissection is also important in disease staging and selection of adjuvant treatment [6] [7] [8] [9] ; however, the appropriate extent of lymphadenectomy remains controversial, as does the number of nodes required to achieve good lymphadenectomy. Even if extended lymphadenectomy appears to provide a more accurate staging and to enhance survival, it constitutes greater surgical trauma and might increase postoperative morbidity [6, 7, 10, 11] . The extent of lymphadenectomy may be individualized according to the pre-and peri-operative LN staging and thereby reduce overtreatment and patient morbidity.
The sentinel lymph node (SN) is considered to be the first LN or group of LNs into which a primary tumour drains. Sentinel node biopsy (SNB) is a successful surgical procedure for evaluating LN metastasis in the treatment of several tumour types, such as breast cancer, melanoma and penile cancer [12, 13] . In BCa, the reliability of SNB is incompletely studied. Moreover, the lymphatic drainage of the urinary bladder is not fully understood [14, 15] . Hence, understanding the pelvic LN anatomy is essential for evaluating and mapping LN metastases in BCa.
In the present prospective clinical trial, we investigated systematically the reliability of the SNB technique for detecting pathological LNs during RC in patients with BCa. We also examined the significance of the primary tumour location in the bladder in predicting the site of LN metastases, and the prognostic significance of LN metastasis density on survival.
Materials and Methods

Patient Material and Study Design
This was a prospective clinical trial based on the SN concept. It was conducted during the period 2005-2011 at the University Hospital Link€ oping, Sweden, and was approved by the Regional Ethics Committee (ref. Lu 01-48 and Li 03-268). Prior to inclusion, patients were invited to participate, and received written and oral information about the study. Patients were included only after written consent had been obtained.
All patients who were planned for treatment with open cystectomy and lymphadenectomy as treatment for BCa with pathological category pT1-pT4 were included. Operations were performed with curative intent. Patients with preoperatively known distant metastases (M1), previous radiotherapy of the pelvis, and/or previous pelvic surgery were excluded from the study.
Surgical Procedure
After general anaesthesia and before the start of RC,1 mL 99mTc-nanocolloid (70 MBq/mL) and 1 mL Patent Blue â (Sigma-Aldrich, Stockholm, Sweden) were injected at four sites around the tumour margin in the detrusor muscle. In cases of more than one tumour, the injections were carried out around the largest one. Tumour locations in the urinary bladder were noted. The bladder wall was divided into regions according to a standard protocol as follows: the apex; right side; left side; posterior side; anterior wall; and trigone.
Radical cystectomy and pelvic lymphadenectomy were performed in all patients. In order not to affect lymphatic drainage from the bladder, LN mapping and lymphadenectomy were performed prior to RC. Lymphadenectomy was performed systematically with defined anatomical landmarks. The cranial limit of the LN dissection was at the level of the ureteric crossing of the common iliac vein immediately superior to the confluence of the external and internal iliac veins. In 55 patients lymphadenectomy was performed to the aortic bifurcation at the decision of the operating surgeon. The caudal extension of LN dissection was at the level of Cooper's ligament, with the genitofemoral nerve as the lateral boundary. On both sides of the pelvis, lymphatic and connective tissue were removed separately from the following four anatomical stations: obturator; external iliac; internal iliac; and common iliac.
A handheld gamma probe (Neoprobe 2000 â ; Neoprobe Corp) was used to detect SNs in tissue removed from each anatomical region, outside the body at a distance from the radioactive bladder. Tissue samples expressing radioactivity were defined as SN stations and were sent separately for pathological evaluation. After completing lymphadenectomy, the anatomical sites for each lymphatic station were scanned with the gamma probe for additional tissue expressing radioactivity, which was also sent for pathological examination.
Histopathological Evaluation
All LNs, including SNs, were defined and analysed separately. The entire lymphatic tissue was paraffin-embedded and sectioned for subsequent routine diagnostic histopathological evaluation. Moreover, all the LNs were sectioned at two additional levels situated at 0.5 mm and 1.0 mm from the initial section, respectively. The purpose of re-sectioning all the LNs was to detect whether further sectioning would show additional metastases that could not be found in the initial routine pathological examination [16] .
All original primary bladder tumours and LN slides (used in the initial routine diagnostic histopathology) as well as the new LN sections were re-evaluated by an experienced uropathologist (H.O.). Primary tumours were graded according to the WHO 1999 and WHO 2004 systems, as well as the TNM 2010 classification system [17] , and were examined for the presence of lymphovascular invasion (LVI) without vessel-specific immunohistochemical staining. The histopathological examination of primary tumours and LNs was performed separately. The pathologist was blinded to the data from the study and assessed LNs before the primary tumours.
Definitions and Statistical Analysis
Statistical analysis was performed using SPSS All other differences between groups were calculated using the chi-squared test and logistic regression analysis. Univariate Cox proportional hazards analysis and KaplanMeier analysis with the log-rank test were used for survival analysis.
Lymph node metastasis density (LNMD) is defined as the proportion of pathological LNs in relation to the total number of LNs removed in each patient after lymphadenectomy. To evaluate the performance of LNMD means as a cut-off value, we used receiver-operating characteristic analysis. Sensitivity and 1-minus specificity data over cancer-specific survival as outcomes were used, and area under curve (AUC), in this case 0.74, was calculated with 95% CIs for LNMD means as dichotomous variable. LVI was defined as tumour cells within or attached to the wall of a vascular space without muscular layer.
Results
Of the 103 patients included in the study, 80 (77%) were male. The median age of the patients was 69 years. Seventyone patients (69%) had non-organ-confined tumours (T3 or T4 tumour stage) and all patients had negative surgical margins. A total of 3 253 LNs were sectioned at three levels and examined for the presence of metastases. The mean (range) number of harvested LNs was 31 (7-68) per patient. LN metastasis was found in 41 (40%) of the patients, of whom 11 (10.7%) had single LN metastasis (N1 stage) and 30 (29.1%) had multiple LN metastases (N2 stage). Seventy-five percent of patients had tumours which involved more than one region in the urinary bladder ( Table 1) . The location and number of LN stations dissected, pathological positive stations, SN location and pathologically positive SNs are summarized in Fig. 1 .
Detection of Sentinel Nodes
An SN was detected in 83 (80%) patients, 20 (25%) of whom had pathological SNs. Metastasis occurred in single SNs in 17 patients (85%). One patient had four pathological SNs, and the remaining two patients had two pathological SNs each. In three N1 patients, the only positive LN was also SN.
Based on the principle that metastasis occurs in anatomical order from the SN to the adjacent LN, the diagnostic tests for SNs were performed separately for each anatomical station in the pelvis. The sensitivity and specificity for detecting metastatic disease by SNB varied between LN stations, with averages of 67% and 90%, respectively. The negative and positive predictive value ranges were 63-100% and 0-99%, respectively ( Table 2 ). In patients with detectable nonpathological SNs (n = 70), 13 (19%) had LN metastasis in other pelvic LN specimens.
Looking only at the side of the LNs involved instead of particular stations, sensitivity and specificity for the right side were 77% and 100%, respectively, and for the left side they were 72% and 100%, respectively (Table 2) .
Clinical Significance of LNMD
The mean LNMD in all patients was 8%. In relation to tumour-specific survival, the highest AUC was identified for an LNMD value of 8% (AUC 0.74; 95% CI 0.67-0.87). Based on these data, an LNMD value of 8% was used as a cut-off in further statistical analysis. Patients with LNMD ≥8% had a mean survival time of 22 months compared with patients with LNMD <8%, who had a mean survival time of 53 months (P < 0.001; Fig. 2 ).
Significance of Primary Tumour Location in the Bladder
Locations of the primary tumour in the bladder wall were analysed in relation to the site of the metastasis and N-stage. To identify the pattern of lymphatic drainage to the pelvic LNs, we compared primary tumour location and the distribution of pathological LNs in the pelvis.
In the presence of one or multiple tumours located in multiple bladder regions, it became difficult to ensure a correct drainage route from the respective bladder regions; therefore, patterns of LN metastasis from one single bladder region were expected to be more unambiguous.
Pelvic LN metastasis from tumours in the lateral bladder wall was mainly (70% of cases) channelled to the ipsilateral side of the pelvis (Fig. 3A-C 
Association between Patient and Tumour Characteristics, and Death from Bladder Cancer
Lymph node metastatic density ≥8% was associated with advanced N-stage tumour recurrence and poor survival. Patients with N0 stage (n = 62, 60%), LNMD <8% (n = 14, 14%) and LNMD ≥8% (n = 27, 26%) had cancerspecific survival rates of 71%, 43% and 19%, respectively (P < 0.001). Patients with organ-confined (n = 32, 31%) and non-organ-confined tumours (n = 71, 69%) had a cancer-specific survival rates of 81% and 41% after 5 years, respectively (P < 0.001). Patients with LVI (n = 67, 65%) and patients without LVI (n = 36, 35%) had cancer-specific survival of 78% and 40%, respectively (P < 0.001). The association between pathological LN status and clinicopathological data is reported in Table 3 . Non-organconfined tumours and LVI were significantly associated with pathological LN. The relationship between cancerspecific death and clinicopathological data is shown in Table 4 . Non-organ-confined tumours, pathological LN status and LVI were associated with death from BCa.
The 5-year cancer-specific survival rate for organ-confined tumours was 70% for patients with N0 stage and 60% for patients with N1-2 stages, respectively; however, the number of patients with pathological LNs in organ-confined tumours was too low for any conclusions to be drawn. The corresponding figures for non-organ-confined tumours for the corresponding groups were 60% and 20%, respectively (logrank v 2 = 12.73; P < 0.001; Fig. 4A,B) .
Discussion
In the present study, we detected SNs in 80% of the cases, and observed a mean sensitivity and specificity of 67% and 
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Pathological LN with LNMD ≥ 8% n = 27 75,00 50,00 Observation time (months) Cancer-specific cumulative survival 25,00 ,00 125,00 Patients with LNMD ≥8% had shorter cancer-specific survival. 90%, respectively for each lymphatic station. The SNB technique showed a low test sensitivity of 67%. Moreover, tumours in the axial parts of the bladder resulted in LN metastasis almost equally in both the right and left sides of the pelvis, whereas 30% of tumours in the lateral sides of the bladder wall were associated with LN metastasis in the contralateral side of the pelvis. It has been shown that technical factors might influence the detection rate. The volume of injection was related to the detection rate in colon cancer for both in vivo and ex vivo techniques [18] .These findings indicate that BCa metastasis to pelvic LNs is difficult to predict accurately and therefore SNB is of low clinical value for the detection of pathological pelvic LN. In a study similar to the present one, in 75 patients, Liedberg et al. [15] reported a 19% false-negative SN rate. The authors stated that a false-negative SN rate might be explained by the rerouting of afferent lymphatic drainage as a consequence of obstructed pathological SNs, thereby resulting in no radiotracer uptake in these LNs. This phenomenon is described in several other tumour types [19, 20] , and may help explain the low sensitivity rate in the present study. Sherif et al. [14] examined the possibility of detecting SNs in a small study of 13 patients with BCa. There were no false-negative SNs. They concluded that SNs can be identified in these patients with a technique based on lymphoscintigraphy and dye marker. In a systemic review, van der Zaag et al. [21] show an overall sensitivity rate of SN mapping in patients with colorectal cancer of 70%. Hence, based on SN findings in the present study and previous reports, SNB is not expected to be a reliable technique for detecting and mapping pelvic lymphatic metastasis during RC for BCa.
Lymph node metastatic density ≥8% is a useful tool in predicting cancer-specific survival. LNMD is a conceptual estimation of tumour burden in cancer, and incorporates the extent of surgical staging. In two separate retrospective studies, Herr [22] and Stein et al. [23] introduced an LNMD cut-off rate of 20%, which was superior to the TNM staging in predicting cancer-specific survival. In both these analyses, LNMD was arbitrarily determined retrospectively. Knowing that LNMD is influenced by surgical technique and the accuracy of pathological analysis, LN dissection in the present study was performed in standardized templates, and the pathological analysis was re-evaluated systematically by an experienced uropathologist. LNMD was then statistically estimated using receiver- operating characteristic analysis and a cut-off rate of 8% was found, which was substantially lower than previously reported values. Furthermore, LNMD ≥8% was associated with advanced tumour stages and shorter survival time and had a significant prognostic value (hazard ratio 6.87) for death from BCa. These findings support previous observations [24, 25] , which assume that LNMD is a sensitive determinant of surgical outcome and can be used clinically for risk assessment of patients with regard to prognosis. In line with these data, we believe that LNMD could also be used in designing, evaluating and reporting clinical trials.
In the present study we found a significant association between tumour location in the left and right sides of the bladder wall and the location of pathological LNs to the corresponding side of the pelvis. Tumours in the central parts of the bladder wall were associated with bilateral pelvic LN metastasis. This issue has been studied by Leissner et al. [6] in a prospective multicentre study. These authors identified 29 patients, of whom 13 had strictly unilateral BCa, with only one positive node. In 10 of the 13 patients, the metastasis was located on the same side, and in three patients on the opposite side of the tumour, which was a similar result to that of the present study.
Lymphovascular invasion is related to LN tumour involvement and BCa-specific mortality. Herrmann et al. [26] reported that LVI had an independent prognostic impact and was associated with impaired survival. These authors suggested that LVI should be determined routinely in RC specimens to identify patients who may benefit from adjuvant systemic therapy.
A weakness of the present study on the SN concept was that we used no lymphoscintigraphy and did not identify the lymphatic channels as originally described by Tanis et al. [13] , Nieweg et al. [27] and Morton et al. [28] . Furthermore, the LN dissection was performed to the level of the ureter, crossing at the beginning of the common iliac vessels, as a standard procedure. This might have had an influence on both LN and SN detection; however, Bochner et al. [29] found that extended dissection to the aortic bifurcation offered no staging advantage over limited dissection to the iliac bifurcation.
Another factor which might have affected the results of the present study is the number of previous transurethral resections of bladder tumours, which might be associated with an altered lymphatic drainage and an increased risk of nodal metastases, possibly to different nodal sites, as suggested by Leissner et al. [6] .
Finally, it was sometimes difficult to identify the exact anatomical location of the LNs dissected, especially in the triangular area between the common, external and internal iliac arteries; therefore, we also analysed the right and the left sides separately.
In conclusion, SNB of pelvic LNs in RC and lymphadenectomy for the management of BCa is not a reliable technique for identifying LN metastasis because of the low sensitivity and anatomical variation of lymphatic drainage from the bladder to the pelvic LNs. Nevertheless, LNMD and LVI have a significant prognostic impact in BCa, and we propose to use these endpoints in the clinical context and as a clinical variable in oncological and surgical research on BCa. 
